1. Pal, G., V. Rohil, R. Akhtar, T. Behl, S. Bharati, T.R. Swain, M. Imran and J. Jena, 2017. Pharmacological and biochemical modulation of stress markers by L-Name and L-Ascorbic acid in chronic restraint model in Wistar rats. Asian J. Med. Sci., 8: 15-20.
2. Behl, T., I. Kaur, H. Goel and A. Kotwani, 2016. Implications of the endogenous PPAR-gamma ligand, 15-deoxy-delta-12, 14-prostaglandin J2, in diabetic retinopathy. Life Sci., 153: 93-99.
   Direct Link  |  
3. Behl, T., I. Kaur and A. Kotwani, 2016. Role of leukotrienes in diabetic retinopathy. Prostaglandins Other Lipid Mediators, 122: 1-9.
   Direct Link  |  
4. Behl, T., I. Kaur and A. Kotwani, 2016. Insights into Pathways leading to Diabetes Mellitus and Complications. Lambert Academy Publishers, Germany, Pages: 73.
5. Behl, T., I. Kaur and A. Kotwani, 2016. Implication of oxidative stress in progression of diabetic retinopathy. Surv. Ophthalmol., 61: 187-196.
   Direct Link  |  
6. Behl, T. and A. Kotwani, 2016. Proposed mechanisms of Terminalia catappa in hyperglycaemia and associated diabetic complications. J. Pharm. Pharmacol., .
   Direct Link  |  
7. Behl, T. and A. Kotwani, 2016. Downregulated brain-derived neurotrophic factor-induced oxidative stress in the pathophysiology of diabetic retinopathy. Can. J. Diabetes, .
   Direct Link  |  
8. Tapan Behl, Ishneet Kaur 2015. Herbal Plants: A Boon in the Treatment of Diabetic Retinopathy Pharmacologia, 6: 1-10.
   CrossRef  |  
9. Behl, T., I. Kaur, H. Goel and A. Kotwani, 2015. Significance of the antiangiogenic mechanisms of thalidomide in the therapy of diabetic retinopathy. Vasc. Pharmacol., .
   Direct Link  |  
10. Behl, T., I. Kaur and A. Kotwani, 2015. Role of endocannabinoids in the progression of diabetic retinopathy. Diabetes Metab. Res. Rev., 32: 251-259.
    Direct Link  |  
11. Behl, T., I. Kaur and A. Kotwani, 2015. Intricate role of C-reactive protein in disease pathology. Lambert Academic Publishers, Germany, Pages: 51.
12. Behl, T., A. Kotwani, I. Kaur and H. Goel, 2015. Mechanisms of prolonged lithium therapy-induced nephrogenic diabetes insipidus. Eur. J. Pharmacol., 755: 27-33.
    Direct Link  |  
13. Behl, T. and A. Kotwani, 2015. Possible role of endostatin in the antiangiogenic therapy of diabetic retinopathy. Life Sci., 135: 131-137.
    Direct Link  |  
14. Behl, T. and A. Kotwani, 2015. Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy. Pharmacol. Res., 99: 137-148.
    Direct Link  |  
15. Thakur, K., M. Nagpal, G. Aggarwal, R. Kaur, S. Singh, T. Behl and U.K. Jain, 2014. A review on solid dispersion. World J. Pharm. Pharm. Sci., 3: 173-187.
16. Sudan, P., S. Sudan, T. Behl and M. Sharma, 2014. A critical insight into the intricate role of plant hormones in growth and development phase. Pharm. Tutor, 2: 87-89.
    Direct Link  |  
17. Saini, D., T. Behl, I. Kaur, M. Nagpal, H. Goel and R.K. Pandey, 2014. Ameliorative effects of murraya koenigii in chronic constriction injury of sciatic nerve induced neuropathic pain in rats. World J. Pharm. Res., 3: 955-972.
18. Rattan, R., T. Behl, P. Sudan, R.W. Misri and D. Jaglan, 2014. Biochemistry of prostaglandins and cyclooxygenase in cancer. Pharm. Tutor, 2: 46-58.
    Direct Link  |  
19. Kaur, P., T. Behl, S. Bhardwaj and H. Goel, 2014. Ameliorative effects of Allium cepa in ethanol induced neuropathic pain in rats. World J. Pharm. Res., 3: 1075-1090.
20. Kaur, N., T. Behl and A. Kotwani, 2014. Ameliorative effects of Cedrus deodara wood extract against streptozotocin induced diabetic nephropathy in rats. Asian J. Biochem. Pharm. Res., 3: 91-101.
21. Gupta, V., M. Nagpal, I. Khan, I. Aggarwal, R. Kaur, S. Singh, T. Behl and U.K. Jain, 2014. A review on non-ionic surfactant based organogel for transdermal delivery. World J. Pharm. Pharm. Sci., 3: 150-163.
22. Gupta, V., M. Nagpal, G. Aggarwal, R. Kaur, S. Singh, T. Behl and U.K. Jain, 2014. Formulation, development and evaluation of non-ionic surfactant based organogel for transdermal delivery of acyclovir. Int. J. Innovative Pharm. Sci. Res., 2: 1297-1300.
23. Bhardwaj, S., T. Behl, K. Singh and P.L. Sharma, 2014. Evaluation of renoprotective activity of mesozeaxanthin in streptozotocin induced diabetic rats. World J. Pharm. Res., 3: 1895-1905.
24. Behl, T., P. Kaur, D. Saini, I. Singh, H. Goel and R.K. Pandey, 2014. A Critical Insight into Complications of Alcohol. World J. Pharm. Pharm. Sci., 3: 1222-1238.
25. Behl, T., N. Kaur, I. Kaur, H. Goel and R.K. Pandey, 2014. Mediators involved in diabetic nephropathy: an updated review. Asian J. Biochem. Pharm. Res., 2: 134-149.
26. Behl, T., J.R. IshneetKaur and R. Pandey, 2014. Role of von hippel-lindau gene mutation in renal cancer. Innovations Pharm. Pharmacother., 2: 357-362.
    Direct Link  |  
27. Behl, T., I. Kaur, R.W. Misri and H. Goel, 2014. Resealed Erythrocytes as A Potential Drug Carrier: A Review. Pharm. Tutor, 2: 73-78.
    Direct Link  |  
28. Behl, T., I. Kaur, P. Sudan, M. Sharma and H. Goel, 2014. Von Hippel-Lindau (VHL) Syndrome: A Critical Insight. Pharm.Tutor, 2: 114-118.
    Direct Link  |  
29. Behl, T., I. Kaur, H. Goel and R.K. Pandey, 2014. PKC activation in the pathogenesis of various diabetic complications. Asian J. Biochem. Pharm. Res., 2: 232-245.
30. Behl, T., I. Kaur, H. Goel and R.K. Pandey, 2014. Mutational Analysis of Androgen Insensitivity Syndrome. Indo Am. J. Pharm. Res., 4: 3231-3238.
31. Behl, T., I. Kaur, H. Goel and R.K. Pandey, 2014. Intricate role of gene mutations in various disease pathology. Adv. J. Pharm. Life Sci., 2: 18-39.
    Direct Link  |  
32. Behl, T., I. Kaur, H. Goel and R.K. Pandey, 2014. Diabetic nephropathy and diabetic retinopathy as major health burdens in modern era. World J. Pharm. Pharm. Sci., 3: 370-387.
33. Behl, T., I. Kaur, H. Goel and R.K. Pandey, 2014. DNA Biosensors: An intricate tool for disease diagnosis. Int. Res. J. Inventions Pharm. Sci., 2: 186-194.
34. Behl, T., I. Kaur, C. Kaur, S. Sihag and S. Medapati, 2014. Insight into the pathogenesis of progressive multifocal leucoencephalopathy. Int. Res. J. Inventions Pharm. Sci., 2: 195-201.
35. Behl, T., I. Kaur, C. Kaur, S. Sihag and S. Medapati, 2014. Congenital hypothyroidism: An updated review of its pathogenesis. Int. J. Res. Pharm. Sci., 4: 1-7.
    Direct Link  |  
36. Behl, T., H. Goel, I. Kaur, P. Sudan, M. Sharma, R.W. Misri, S.R. Sihag, P. Patyal and S. Medapati, 2014. Role of C reactive protein in diabetes mellitus and its associated complications. Indo Am. J. Pharm. Res., 4: 5315-5320.
37. Behl, T., D. Saini, P. Kaur, H. Goel, S. Bhardwaj and R. Pandey, 2014. A review on neuropathic pain: An approach towards treatment. World J. Pharm. Res., 3: 1877-1891.
38. Behl, T. and A. Kotwani, 2014. Terminalia catappa in the treatment of diabetes mellitus. Asian J. Biochem. Pharm. Res., 3: 1-10.
39. Behl, I.K., H. Goel and R.K. Pandey, 2014. An insight into the genetic study and pathogenesis of the colorectal cancer. Global J. Med. Res., 14: 29-36.
    Direct Link  |  
40. Behl, T., M. Sharma and H. Goel, 2013. Neurofibromatosis. Pharm. Tutor, .
    Direct Link  |  
41. Behl, T., I. Kaur, P. Sudan, S. Sudan, P. Patyal, R.K. Pandey and H. Goel, 2013. Alcoholic Polyneuropathy: An Update. Innovations Pharm. Planet, 2: 79-89.
42. Yadav, H.N., M. Singh, P.L. Sharma, D. Mittal, T. Behl and A.P. Kuar, 2012. Possible role of cyclooxygenase-2 in remote aortic preconditioning induced cardioprotection in rat heart. Pharmacologia, 3: 1-8.
    CrossRef  |  Direct Link  |  
43. Behl, T., N. Chauhan and H.N. Yadav, 2011. Alternatives to animal testing: A vantage over animal models. Clin. Res. Plus, 2011: 47-51.